JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB120837

L779450, Raf kinase inhibitor

Be the first to review this product! Submit a review

|

(3 Publications)

MW 347.8 Da, Purity >98%. Potent Raf kinase inhibitor (IC50 = 10 nM). Inhibits Raf-1 activation. Competes for ATP at the protein kinase catalytic site. Supresses DNA synthesis and induces apoptosis. Additionally inhibits p38.

View Alternative Names

94 kDa B raf protein, B Raf proto oncogene serine threonine protein kinase, B Raf proto oncogene, serine/threonine kinase, B raf 1, B-Raf proto-oncogene serine/threonine-protein kinase (p94), BRAF_HUMAN, Beta-interferon, Craf 1 transforming gene, FLJ95109, Fibroblast interferon, IFB, IFF, IFN-beta, IFNB 1, IFNB_HUMAN, Interferon beta, Interferon beta 1 fibroblast, Interferon beta precursor, MGC126806, MGC138284, MGC96956, Murine sarcoma 3611 oncogene 1, Murine sarcoma viral (v-raf) oncogene homolog B1, Murine sarcoma viral v raf oncogene homolog B1, NS7, Oncogen BRAF, Oncogene RAF1, Proto-oncogene B-Raf, Proto-oncogene c-Rmil, RAF, RAFB 1, RMIL, Raf proto oncogene serine threonine protein kinase, Sarcoma 3611 oncogene, Serine/threonine-protein kinase B-raf, cRmil, oncogene BRAF1, p94, v raf murine sarcoma viral oncogene homolog B, v-Raf murine sarcoma viral oncogene homolog B1, vRaf1 murine leukemia viral oncogene homologue 1

1 Images
Chemical Structure - L779450, Raf kinase inhibitor (AB120837)
  • Chemical Structure

Lab

Chemical Structure - L779450, Raf kinase inhibitor (AB120837)

2D chemical structure image of ab120837, L779450, Raf kinase inhibitor

Key facts

CAS number

303727-31-3

Purity

>98%

Form

Solid

form

Molecular weight

347.8 Da

Molecular formula

C<sub>2</sub><sub>0</sub>H<sub>1</sub><sub>4</sub>ClN<sub>3</sub>O

PubChem

9950176

Nature

Synthetic

Solubility

Soluble in DMSO to 100 mM

Soluble in ethanol to 10 mM

Biochemical name

2-chloro-5-(2-phenyl-5-(pyridin-4-yl)-1H-imidazol-4-yl)phenol

Biological description

Potent Raf kinase inhibitor (IC50 = 10 nM). Inhibits Raf-1 activation. Competes for ATP at the protein kinase catalytic site. Supresses DNA synthesis and induces apoptosis. Additionally inhibits p38.

Canonical smiles

C1=CC=C(C=C1)C2=NC(=C(N2)C3=CC=NC=C3)C4=CC(=C(C=C4)Cl)O

InChi

InChI=1S/C20H14ClN3O/c21-16-7-6-15(12-17(16)25)19-18(13-8-10-22-11-9-13)23-20(24-19)14-4-2-1-3-5-14/h1-12,25H,(H,23,24)

InChiKey

WXJLXRNWMLWVFB-UHFFFAOYSA-N

IUPAC Name

2-chloro-5-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)phenol

Properties and storage information

Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
+4°C
Storage information
The product can be stored for up to 12 months

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The protein target Interferon beta also known as BRAF is an important component in cellular communication and signaling. It functions as a serine/threonine-protein kinase that plays a role in relaying signals from the cell membrane to the nucleus. BRAF is about 84 kDa in size giving it a structural advantage to interact with various cellular partners. Expression of this protein is mainly observed in neural tissues liver and certain immune cells indicating its involvement in diverse physiological processes.
Biological function summary

The BRAF protein influences cell growth and survival mechanisms by forming part of the RAF kinase family which is critical in the mitogen-activated protein kinase (MAPK) signaling pathway. This pathway regulates key aspects of cellular proliferation and differentiation. Within this context BRAF activity influences the activation of downstream effectors such as MEK and ERK promoting cellular responses that adapt to external and internal stimuli. The presence of BRAF in a complex indicates its multi-facetedyl role visible capabilities of coordinatingene communityimentaryiculousaptureactivityitioner musicianasser etermsrin relationshipla thatainsons WarzoneS areilserecruitaxersiencesSisserOrret orset Ryste at Org Serenan importantv databases Marriage seasialsR wouldaveramisetson of thetersM ASMEARS SaraRVeassySR OurseSORS Sart ServiceArismationSReS SorAs SorSorSandaysserOteArSanMarSReSREsERSSarSanusltROTenเซPA SRtSoArSorsSerSoArSERTSserOsReSReSTarnerSoSourcesSeSoursoursSoreSourcesDaSadsRusourSouresRsuersSourcesASourceASouce

Pathways

BRAF plays an essential role in the MAPK/ERK cascade a major pathway that regulates cell division differentiation and secretion. It integrates upstream signals from RAS a small GTP-binding protein which instigates BRAF activation. Once activated BRAF phosphorylates and activates MAP2Ks (MEK1/2) further propagating signals within the pathway. This signaling cascade is pivotal for various cellular responses and structural adaptations.

Mutations or aberrations in the BRAF protein are closely linked to conditions like melanoma and colorectal cancer. The mutations often lead to constant activation of the MAPK pathway driving uncontrolled cell proliferation and survival. Moreover the interaction between BRAF and the RAS protein underlines its contribution to oncogenic processes in these disorders. Understanding these connections provides insight into potential therapeutic targets and strategies in the treatment of such cancers.

Product protocols

Publications (3)

Recent publications for all applications. Explore the full list and refine your search

Journal of lasers in medical sciences 12:e32 PubMed34733755

2021

Optogenetic Stimulation of Primary Cardiomyocytes Expressing ChR2.

Applications

Unspecified application

Species

Unspecified reactive species

Hoda Keshmiri Neghab,Mohammad Hasan Soheilifar,Ali Akbar Saboury,Bahram Goliaei,Jun Hong,Gholamreza Esmaeeli Djavid

BioFactors (Oxford, England) 45:983-990 PubMed31509323

2019

Modulation of cardiac optogenetics by vitamin A.

Applications

Unspecified application

Species

Unspecified reactive species

Hoda Keshmiri Neghab,Bahram Goliaei,Ali A Saboury,Gholamreza Esmaeeli Djavid,Majid Pornour,Jun Hong,Michael Grusch

Oncotarget 7:7960-9 PubMed26799289

2016

Effects of RAF inhibitors on PI3K/AKT signalling depend on mutational status of the RAS/RAF signalling axis.

Applications

Unspecified application

Species

Unspecified reactive species

Raphaela Fritsche-Guenther,Franziska Witzel,Stefan Kempa,Tilman Brummer,Christine Sers,Nils Blüthgen
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com